The Potential of Natural Levodopa in Koro Benguk Seeds (Mucuna pruriens) for Treatment in Parkinson's Disease
Authors
Nyoman Ayu Anindya Maharani , Belynda Rahmalia Sanceska Wahyudi , Aisya Yafis Iqlima , Aisya Nur Abida , Maida sania salsabila , Devi Chandra Kirana , Andina Nabilah Mario , Herpan Syafii HarahapDOI:
10.29303/jbt.v24i3.7265Published:
2024-07-27Issue:
Vol. 24 No. 3 (2024): July - SeptemberKeywords:
Mucuna pruriens, levodopa, Parkinson's disease.Articles
Downloads
How to Cite
Downloads
Metrics
Abstract
Mucuna pruriens also known as velvet bean (koro benguk) is a plant commonly found in tropical regions, including Indonesia. Mucuna pruriens is known to contain high levels of Levodopa, making it a potential natural treatment for Parkinson's disease. Parkinson's disease is a neurodegenerative disorder characterized by tremors, rigidity, bradykinesia, and postural instability. The estimated global incidence of Parkinson's disease in 2024 is expected to reach 12 to 17 million patients. Synthetic Levodopa has been the standard and proven effective therapy for Parkinson's disease. The method used in the preparation of this article is a literature review by collecting relevant and focused articles. The literature sources were accessed through comprehensive searches in three databases (Pubmed, Google Scholar, and Researchgate) from 2014 to 2024, using keywords such as “Mucuna pruriens,” “Levodopa,” and “Parkinson's disease.” The result of the literature review indicates that Levodopa is the dominant active component found in Mucuna pruriens compared to other compounds. The naturally occurring Levodopa functions as a precursor to dopamine, which plays a role in the treatment of Parkinson's disease, thus it can be developed into a complementary therapy in regions with abundant resources.
References
Armstrong, M. J. and Okun, M. S. (2020) ‘Diagnosis and Treatment of Parkinson Disease: A Review’, JAMA - Journal of the American Medical Association, 323(6), pp. 548–560. doi: 10.1001/jama.2019.22360.
Aryal, S., Skinner, T., Bridges, B., & Weber, J. T. (2020). The Pathology of Parkinson's Disease and Potential Benefit of Dietary Polyphenols. Molecules (Basel, Switzerland), 25(19), 4382. https://doi.org/10.3390/molecules25194382
Baby, C., Kaur, S., Singh, J., & Prasad, R. (2023). Velvet bean (Mucuna pruriens): A sustainable protein source for tomorrow. Legume Science, 5(3). https://doi.org/10.1002/leg3.178
Barnhill, L. M., Murata, H., & Bronstein, J. M. (2020). Studying the Pathophysiology of Parkinson's Disease Using Zebrafish. Biomedicines, 8(7), 197. https://doi.org/10.3390/biomedicines8070197
Branco, D. M., Arduino, D. M., Esteves, A. R., Silva, D. F., Cardoso, S. M., & Oliveira, C. R. (2010). Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Frontiers in aging neuroscience, 2, 17. https://doi.org/10.3389/fnagi.2010.00017
Brás, I. C., & Outeiro, T. F. (2021). Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. Cells, 10(2), 375. https://doi.org/10.3390/cells10020375
Brundin, D. K. S. C. M. T. P. (2020) ‘Parkinson disease Epidemiology, Pathology, Genetics and Pathophysiology’, Clin Geriatr Med, 176(5), pp. 139–148. doi: 10.1016/j.cger.2019.08.002.Parkinson.
Carnwath, T., Mohammed, R., & Tsiang, D. (2018). The direct and indirect effects of α-synuclein on microtubule stability in the pathogenesis of Parkinson's disease. Neuropsychiatric disease and treatment, 14, 1685–1695. https://doi.org/10.2147/NDT.S166322
Cassani, E., Cilia, R., Laguna, J., Barichella, M., Contin, M., Cereda, E., Isaias, I.U., et al. (2016), “Mucuna pruriens for Parkinson’s disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile”, Journal of the Neurological Sciences, The Authors, Vol. 365, pp. 175–180, doi: 10.1016/j.jns.2016.04.001.
Chaudhuri, K. R. et al. (2024) ‘Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study’, Drugs - Real World Outcomes, 11(1), pp. 1–11. doi: 10.1007/s40801-023-00410-1.
Chittasupho, C., Tadtong, S., Vorarat, S., Imaram, W., Athikomkulchai, S., Samee, W., Sareedenchai, V., et al. (2022), “Development of Jelly Loaded with Nanogel Containing Natural L-Dopa from Mucuna pruriens Seed Extract for Neuroprotection in Parkinson’s Disease”, Pharmaceutics, Vol. 14 No. 5, doi: 10.3390/pharmaceutics14051079.
Cilia, R. et al. (2017) ‘Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study’, Neurology, 89(5), pp. 432–438. doi: 10.1212/WNL.0000000000004175.
Dimitry, M.Y., Marie Therèse, B.A., Josiane Edith, D.M., Emmanuel, P.A., Armand, A.B. and Nicolas, N.Y. (2022) ‘Hypolipidemic and antioxidant effects of vegetal milk produced with Mucuna pruriens L. seed in rats fed a high-fat diet’, Heliyon, 8(11). Available at: https://doi.org/10.1016/j.heliyon.2022.e11835.
Fothergill-Misbah, N. et al. (2020) ‘Could Mucuna pruriens be the answer to Parkinson’s disease management in sub-Saharan Africa and other low-income countries worldwide?’, Parkinsonism and Related Disorders, 73, pp. 3–7. doi: 10.1016/j.parkreldis.2020.03.002.
Gunawan, R. et al. (2023) ‘Mucuna pruriens as Nano Herbal Medicine: A Review’, AIP Conference Proceedings, 2569(January). doi: 10.1063/5.0113635.
Habibah, W. T., Rahayu, T., & Ramadhan, M. (2022). Analisis In Silico dan Kuantitatif Senyawa Metabolit Sekunder Senyawa L-DOPA Pada Ekstrak Biji Dan Daun Kacang Koro Benguk (Mucuna pruriens D.C.) menggunakan metode Spektrometri UV-VIS. Metamorfosa: Journal of Biological Sciences, 9(2), 369. https://doi.org/10.24843/metamorfosa.2022.v09.i02.p16
Jagadeesan, A. J. et al. (2017) ‘Current trends in etiology, prognosis and therapeutic aspects of Parkinson’s disease: a review’, Acta Biomedica, 88(3), pp. 249–262. doi: 10.23750/ABM.V88I3.6063.
Johnson, S.L., Park, H.Y., Dasilva, N.A., Vattem, D.A., Ma, H. and Seeram, N.P. (2018), “Levodopa-reduced mucuna pruriens seed extract shows neuroprotective effects against parkinson’s disease in murine microglia and human neuroblastoma cells, Caenorhabditis elegans, and Drosophila melanogaster”, Nutrients, Vol. 10 No. 9, pp. 1–14, doi: 10.3390/nu10091139.
Kamkaen, N., Chittasupho, C., Vorarat, S., Tadtong, S., Phrompittayarat, W., Okonogi, S. and Kwankhao, P. (2022), “Mucuna pruriens Seed Aqueous Extract Improved Neuroprotective and Acetylcholinesterase Inhibitory Effects Compared with Synthetic L-Dopa”, Molecules, Vol. 27 No. 10, pp. 1–13, doi: 10.3390/molecules27103131.
Konishi, F., Furusho, T., Soeda, Y., Yamauchi, J., Kobayashi, S., Ito, M., Araki, T., Kogure, S., Takashima, A. and Takekoshi, S. (2022) ‘Administration of mucuna beans (Mucuna pruriences (L.) DC. var. utilis) improves cognition and neuropathology of 3 × Tg-AD mice’, Scientific Reports, 12(1). Available at: https://doi.org/10.1038/s41598-022-04777-z.
Kowalska, T. (2022), “Thin-Layer Chromatography (TLC) in the Screening of Botanicals–Its Versatile Potential and Selected Applications”, Molecules, Vol. 27 No. 19, p. 6607
Kwon, D.K., Kwatra, M., Wang, J. and Ko, H.S. (2022), “Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies”, Cells, Vol. 11 No. 23, doi: 10.3390/cells11233736.
Lampropoulos, I. C. et al. (2022) ‘Worldwide trends in mortality related to Parkinson’s disease in the period of 1994–2019: Analysis of vital registration data from the WHO Mortality Database’, Frontiers in Neurology, 13. doi: 10.3389/fneur.2022.956440.
Li Zhang and Li Qiangzi (2022) ‘Neuroprotective effects of tanshinone IIA in experimental model of Parkinson disease in rats’, Arabian Journal of Chemistry [Preprint].
Macphee, G. (2018) Parkinson’s disease Pathogenesis and Clinical Aspects, Codon Publication. Brisbane. doi: 10.1201/9781315365428-4.
Maldonado, R. G. (2018) ‘Mucuna and Parkinson’s Disease: Treatment with Natural Levodopa’, Parkinson’s Disease - Understanding Pathophysiology and Developing Therapeutic Strategies. doi: 10.5772/intechopen.74062.
Mulyani, L., Kartadarma, E., Fitrianingsih, S. P., Farmasi, P., Matematika, F., Ilmu, D., & Alam, P. (2016). Manfaat dan Kandungan Kacang Kara Benguk (Mucuna pruriens L.) sebagai Obat Herbal. Prosiding Farmasi, 2(2).
Murakami, H. et al. (2023) ‘Recent Advances in Drug Therapy for Parkinson’s Disease’, Internal Medicine, 62(1), pp. 33–42. doi: 10.2169/internalmedicine.8940-21.
Neha Sharma, M. R., & Moin, S. G. (2017). Dopaminergic agents: back to the basics – A small review. Journal of Applied Pharmaceutical Research, 5(4), 5–7. https://doi.org/10.18231/2348-0335.2017.0008
Pangestiningsih, T., Susmiati, T., & Wijayanto, H. (2017). Kandungan L-3, 4-dihydroxyphenylalanine Suatu Bahan Neuroprotektif pada Biji Koro Benguk (Mucuna pruriens) Segar, Rebus, dan Tempe. Jurnal Veteriner, 18(1), 116–120. https://doi.org/10.19087/jveteriner.2017.18.1.116
Pathania, R., Chawla, P., Khan, H., Kaushik, R. and Khan, M.A. (2020) ‘An assessment of potential nutritive and medicinal properties of Mucuna pruriens: a natural food legume’, 3 Biotech. Springer. Available at: https://doi.org/10.1007/s13205-020-02253-x.
Poddighe, S., De Rose, F., Marotta, R., Ruffilli, R., Fanti, M., Secci, P.P., Mostallino, M.C., Setzu, M.D., Zuncheddu, M.A., Collu, I., Solla, P., Marrosu, F., Kasture, S., Acquas, E. and Liscia, A. (2014) ‘Mucuna pruriens(Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of Parkinson’s disease’, PLoS ONE, 9(10). Available at: https://doi.org/10.1371/journal.pone.0110802.
Poewe, W. et al. (2017) ‘Parkinson disease’, Nature Reviews Disease Primers, 3, pp. 1–21. doi: 10.1038/nrdp.2017.13.
Prasathkumar, M., Anisha, S., Dhrisya, C., Becky, R., & Sadhasivam, S. (2021). Therapeutic and pharmacological efficacy of selective Indian medicinal plants – A review. Phytomedicine Plus, 1(2). https://doi.org/10.1016/j.phyplu.2021.100029
Pulikkalpura, H., Kurup, R., Mathew, P. J., & Baby, S. (2015). Levodopa in Mucuna pruriens and its degradation. Scientific Reports, 5. https://doi.org/10.1038/srep11078
Rai, S. N., Chaturvedi, V. K., Singh, P., Singh, B. K., & Singh, M. P. (2020). Mucuna pruriens in Parkinson’s and in some other diseases: recent advancement and future prospective. In 3 Biotech (Vol. 10, Issue 12). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s13205-020-02532-7
Rahman, M.M., Wang, X., Islam, M.R., Akash, S., Supti, F.A., Mitu, M.I., Harun-Or-Rashid, M., Aktar, M.N., Khatun Kali, M.S., Jahan, F.I., Singla, R.K., Shen, B., Rauf, A. and Sharma, R. (2022) ‘Multifunctional role of natural products for the treatment of Parkinson’s disease: At a glance’, Frontiers in Pharmacology. Frontiers Media S.A. Available at: https://doi.org/10.3389/fphar.2022.976385.
Ramesh, S., & Arachchige, A. S. P. M. (2023). Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature. AIMS neuroscience, 10(3), 200–231. https://doi.org/10.3934/Neuroscience.2023017
Ray Dorsey, E. et al. (2018) ‘Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016’, The Lancet Neurology, 17(11), pp. 939–953. doi: 10.1016/S1474-4422(18)30295-3.
Saramowicz, K., Siwecka, N., Galita, G., Kucharska-Lusina, A., Rozpędek-Kamińska, W., & Majsterek, I. (2023). Alpha-Synuclein Contribution to Neuronal and Glial Damage in Parkinson's Disease. International journal of molecular sciences, 25(1), 360. https://doi.org/10.3390/ijms25010360
Sardjono, R.E., Gunawan, R., Kadarohman, A., Erdiwansyah, Mamat, R. and Khairuddean, M. (2024), “Nanostarch based nanoencapsulation of Mucuna pruriens extract and its evaluation as anti-parkinsonian drug”, Case Studies in Chemical and Environmental Engineering, Elsevier Ltd, Vol. 9 No. August 2023, p. 100562, doi: 10.1016/j.cscee.2023.100562.
Sayyaed, A., Saraswat, N., Vyawahare, N., & Kulkarni, A. (2023). A detailed review of pathophysiology, epidemiology, cellular and molecular pathways involved in the development and prognosis of Parkinson’s disease with insights into screening models. Bulletin of the National Research Centre, 47(1). https://doi.org/10.1186/s42269-023-01047-4
Schulz-Schaeffer W. J. (2015). Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?. Biomolecules, 5(3), 1467–1479. https://doi.org/10.3390/biom5031467
Shimozawa, A., Fujita, Y., Kondo, H., Takimoto, Y., Terada, M., Sanagi, M., Hisanaga, S. I., & Hasegawa, M. (2019). Effect of L-DOPA/Benserazide on Propagation of Pathological α-Synuclein. Frontiers in neuroscience, 13, 595. https://doi.org/10.3389/fnins.2019.00595
Suryawanshi, S. S., Kamble, P. P., Bapat, V. A., & Jadhav, J. P. (2020). Parkinsonism and Potential of Mucuna Beans. www.intechopen.com
Tavares, R.L., de Vasconcelos, M.H.A., Dutra, M.L. da V., D’oliveira, A.B., Lima, M.D.S., Salvadori, M.G. da S.S., Pereira, R. de A., Alves, A.F., Nascimento, Y.M. Do, Tavares, J.F., Guzman-Quevedo, O. and Aquino, J. de S. (2020) ‘Mucuna pruriens administration minimizes neuroinflammation and shows anxiolytic, antidepressant and slimming effects in obese rats’, Molecules, 25(23). Available at: https://doi.org/10.3390/molecules25235559.
Tesoro, C., Lelario, F., Ciriello, R., Bianco, G., Di Capua, A., & Acquavia, M. A. (2022). An Overview of Methods for L-Dopa Extraction and Analytical Determination in Plant Matrices. In Separations (Vol. 9, Issue 8). MDPI. https://doi.org/10.3390/separations9080224
Trist, B. G., Hare, D. J. and Double, K. L. (2019) ‘Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease’, Aging Cell, 18(6), pp. 1–23. doi: 10.1111/acel.13031.
Vidović, M., & Rikalovic, M. G. (2022). Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches. Cells, 11(11), 1732. https://doi.org/10.3390/cells11111732
Vilairat, C., Kobtrakul, K. and Vimolmangkang, S. (2023), “Enhanced Physicochemical Stability of the L-DOPA Extract of Mucuna pruriens Seeds by Adding Phyllanthus emblica”.
Yi, S., Wang, L., Wang, H., Ho, M. S., & Zhang, S. (2022). Pathogenesis of α-Synuclein in Parkinson's Disease: From a Neuron-Glia Crosstalk Perspective. International journal of molecular sciences, 23(23), 14753. https://doi.org/10.3390/ijms232314753
Zhu, H., Lemos, H., Bhatt, B., Islam, B. N., Singh, A., Gurav, A., Huang, L., Browning, D. D., Mellor, A., Fulzele, S., & Singh, N. (2017). Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity. PLoS ONE, 12(9). https://doi.org/10.1371/journal.pone.0183484
License
Copyright (c) 2024 Nyoman Ayu Anindya Maharani, Belynda Rahmalia Sanceska Wahyudi, Aisya Yafis Iqlima, Aisya Nur Abida, Maida sania salsabila, Devi Chandra Kirana, Andina Nabilah Mario, Herpan Syafii Harahap
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
